Allworth Financial LP Acquires 304 Shares of The Cooper Companies, Inc. (NASDAQ:COO)

Allworth Financial LP lifted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 45.8% during the 3rd quarter, Holdings Channel reports. The firm owned 968 shares of the medical device company’s stock after purchasing an additional 304 shares during the quarter. Allworth Financial LP’s holdings in Cooper Companies were worth $107,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently made changes to their positions in COO. Vanguard Group Inc. boosted its position in shares of Cooper Companies by 303.0% during the 1st quarter. Vanguard Group Inc. now owns 23,099,975 shares of the medical device company’s stock valued at $2,343,723,000 after purchasing an additional 17,367,502 shares in the last quarter. Capital World Investors boosted its position in shares of Cooper Companies by 301.7% during the 1st quarter. Capital World Investors now owns 5,654,023 shares of the medical device company’s stock valued at $573,657,000 after purchasing an additional 4,246,519 shares in the last quarter. Janus Henderson Group PLC boosted its position in shares of Cooper Companies by 279.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,437,064 shares of the medical device company’s stock valued at $348,723,000 after purchasing an additional 2,532,186 shares in the last quarter. Bessemer Group Inc. boosted its position in shares of Cooper Companies by 305.2% during the 1st quarter. Bessemer Group Inc. now owns 2,000,910 shares of the medical device company’s stock valued at $203,013,000 after purchasing an additional 1,507,049 shares in the last quarter. Finally, Swedbank AB acquired a new position in Cooper Companies during the 1st quarter worth approximately $139,246,000. Institutional investors own 24.39% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on COO. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research note on Thursday, August 29th. Morgan Stanley upped their price target on Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Jefferies Financial Group raised Cooper Companies from a “hold” rating to a “buy” rating and upped their price target for the stock from $107.00 to $115.00 in a research note on Tuesday, July 16th. Piper Sandler upped their price target on Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Finally, Robert W. Baird upped their price target on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, August 29th. Three equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $117.00.

Cooper Companies Stock Performance

Shares of Cooper Companies stock opened at $104.68 on Friday. The company has a quick ratio of 1.18, a current ratio of 1.99 and a debt-to-equity ratio of 0.33. The company has a market cap of $20.85 billion, a PE ratio of 58.16, a price-to-earnings-growth ratio of 2.53 and a beta of 0.98. The business has a 50 day moving average price of $106.55 and a 200-day moving average price of $96.96. The Cooper Companies, Inc. has a 52 week low of $77.01 and a 52 week high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to the consensus estimate of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. Cooper Companies’s revenue was up 7.8% on a year-over-year basis. During the same period last year, the business posted $0.84 earnings per share. Equities analysts anticipate that The Cooper Companies, Inc. will post 3.65 earnings per share for the current fiscal year.

Insider Activity at Cooper Companies

In related news, CAO Agostino Ricupati sold 1,601 shares of the stock in a transaction that occurred on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the completion of the sale, the chief accounting officer now directly owns 4,818 shares of the company’s stock, valued at approximately $520,488.54. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. In other Cooper Companies news, CAO Agostino Ricupati sold 1,601 shares of the business’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the sale, the chief accounting officer now directly owns 4,818 shares in the company, valued at $520,488.54. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Albert G. White III sold 114,992 shares of the business’s stock in a transaction on Thursday, September 19th. The shares were sold at an average price of $110.53, for a total value of $12,710,065.76. Following the completion of the sale, the chief executive officer now owns 165,273 shares in the company, valued at approximately $18,267,624.69. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 256,373 shares of company stock valued at $27,637,427. 2.00% of the stock is owned by insiders.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.